OraLiva awarded $1.9M National Institute of Dental and Craniofacial Research (NIDCR at NIH) Direct to Phase II SBIR grant for AI-linked cytomics-on-a-chip Read More
OraLiva is launching its platform with a focus on oral cancer, leveraging its proprietary technology, diagnostic models, and cross-indication biomarkers to build a robust pipeline of oncology tests.
US population suffer from oral lesions complications.
Late stage treatment can cost $100K+ per patient.
Today doctors and dentists lack trusted tools to evaluate these oral lesions. In far too many cases these lesions become malignant.
Late detection of different types of solid tumor cancers remains an issue resulting in higher costs for treatment, hospital stays, in addition to often disastrous patient outcomes.
OraLiva Inc. has developed a novel cytology platform to detect the presence of oral, lung, esophageal and colorectal cancer using common biomarker signatures.
OraLiva makes it possible to identify abnormal cells long before they turn into life-threatening cancer.
AI empowered & data-driven fingerprints for early disease detection.
Every part of OraLiva is designed to deliver accuracy, speed, and accessibility for oral cancer detection.
Cartridges tailored for specific use cases, from oral cancer screening to other cytology-based diagnostics.
Non-invasive sampling
biopsy brush.
Sophisticated microfluidics
engine
Point of care cytomics-on-chip analyzers allow for high-content single-cell imaging to be completed anywhere.
Cloud-based AI performs analysis that human beings cannot
Intuitive test results and reports based on high-content single-cell analysis.
Oralive sees cancer better than anyone else.
Join the OraLiva wait list for product launch news and insights designed to support your team and improve early cancer detection in everyday care.
